The impact of highly active antiretroviral therapy on the incidence and outcomes of AIDS-defining cancers in Southern Alberta

HIV Medicine

Volumn 7, Issue 6, 2006, Pages 369-377

  Gingues, S ^a,b   Gill, M John ^a,b  

^a Southern Alberta Clinic   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

HAART; HIV; Invasive cervical cancer; Kaposi's sarcoma; Non Hodgkin's lymphoma

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CANADA; CANCER INCIDENCE; CANCER INVASION; CANCER MORTALITY; CLINICAL FEATURE; CONTROLLED STUDY; DATA BASE; DISEASE SEVERITY; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MEDICAL RECORD REVIEW; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; OUTPATIENT DEPARTMENT; PATIENT CARE; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; TREATMENT FAILURE; UTERINE CERVIX CANCER; UTERINE CERVIX DYSPLASIA;

ALBERTA; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIV INFECTIONS; HUMANS; INCIDENCE; LYMPHOMA, AIDS-RELATED; LYMPHOMA, NON-HODGKIN; MALE; PREVALENCE; SARCOMA, KAPOSI; UTERINE CERVICAL DYSPLASIA; UTERINE CERVICAL NEOPLASMS;

EID: 33746433981     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2006.00395.x     Document Type: Review

References (39)

1. Castro HG, Ward JW, Slutska L, Baehler JW, Jaffo HW, Bertrelman RL for National Centre for ID Division of AIDS. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992; 41: 1-19.
2. Ebrahim SH, Abdullah AS, McKenna M, Hamers FF. AIDS-defining cancers in Western Europe, 1994-2001. AIDS Patient Care STDS 2004; 18: 501-508.
3. Bedimo R, Chen RY, Accortt NA et al. Trends in AIDS-defining and non-AIDS-defining malignancies among HIV-infected patients: 1989-2002. Clin Infect Dis 2004; 39: 1380-1384.
4. Launay O, Guillevin L. [Epidemiology of HIV-associated malignancies] [French]. Bull Cancer 2003; 90: 387-392.
5. Monini P, Sgadari C, Toschi E, Barillari G, Ensoli B. Antitumour effects of antiretroviral therapy. Nat Rev Cancer 2004; 4: 861-875.
6. Pantanowitz L, Dezube BJ. Advances in the pathobiology and treatment of Kaposi sarcoma. Curr Opin Oncol 2004; 16: 443-449.
7. Krentz HB, Kliewer G, Gill MJ. Changing mortality rates and causes of death for HIV-infected individuals living in Southern Alberta, Canada from 1984 to 2003. HIV Med 2005; 6: 99-106.
8. Orem J, Otieno MW, Remick SC. AIDS-associated cancer in developing nations. Curr Opin Oncol 2004; 16: 468-476.
9. Palella FJ Jr, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853-860.
10. International Collaboration on HIV and Cancer. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst 2000; 92: 1823-1830.
11. Lee N, Hogg RS, Yip B et al. Rates of disease progression among human immunodeficiency virus-infected persons initiating multiple-drug rescue therapy. J Infect Dis 2003; 188: 137-141.
12. Mocroft A, Lundgren JD. Starting highly active antiretroviral therapy: why, when and response to HAART. J Antimicrob Chemother 2004; 54: 10-13.
13. Einstein MH, Kadish AS. Anogenital neoplasia in AIDS. Curr Opin Oncol 2004; 16: 455-462.
14. Palefsky JM. Cervical human papillomavirus infection and cervical intraepithelial neoplasia in women positive for human immunodeficiency virus in the era of highly active antiretroviral therapy. Curr Opin Oncol 2003; 15: 382-388.
15. Antinori A, Cingolani A, Alba L et al. Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy. AIDS 2001; 15: 1483-1491.
16. Bower M, Fox P, Fife K, Gill J, Nelson M, Gazzard B. Highly active anti-retroviral therapy (HAART) prolongs time to treatment failure in Kaposi's sarcoma. AIDS 1999; 13: 2105-2111.
17. Gerard L, Galicier L, Boulanger E et al. Improved survival in HIV-related Hodgkin's lymphoma since the introduction of highly active antiretroviral therapy. AIDS 2003; 17: 81-87.
18. Heard I, Palefsky JM, Kazatchkine MD. The impact of HIV antiviral therapy on human papillomavirus (HPV) infections and HPV-related diseases. Antivir Ther 2004; 9: 13-22.
19. Hoffmann C, Wolf E, Fatkenheuer G et al. Response to highly active antiretroviral therapy strongly predicts outcome in patients with AIDS-related lymphoma. AIDS 2003; 17: 1521-1529.
20. Holkova B, Takeshita K, Cheng DM et al. Effect of highly active antiretroviral therapy on survival in patients with AIDS-associated pulmonary Kaposi's sarcoma treated with chemotherapy. J Clin Oncol 2001; 19: 3848-3851.
21. Kostense S, Otto SA, Knol GJ et al. Functional restoration of human immunodeficiency virus and Epstein-Barr virus-specific CD8(+) T cells during highly active antiretroviral therapy is associated with an increase in CD4(+) T cells. Eur J Immunol 2002; 32: 1080-1089.
22. Lebbe C, Blum L, Pellet C et al. Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi's sarcoma. AIDS 1998; 12: F45-F49.
23. McGowan JP, Shah S. Long-term remission of AIDS-related primary central nervous system lymphoma associated with highly active antiretroviral therapy. AIDS 1998; 12: 952-954.
24. Nasti G, Martellotta F, Berretta M et al. Impact of highly active antiretroviral therapy on the presenting features and outcome of patients with acquired immunodeficiency syndrome-related Kaposi sarcoma. Cancer 2003; 98: 2440-2446.
25. Tam HK, Zhang ZF, Jacobson LP et al. Effect of highly active antiretroviral therapy on survival among HIV-infected men with Kaposi sarcoma or non-Hodgkin lymphoma. Int J Cancer 2002; 98: 916-922.
26. Wilkinson J, Cope A, Gill J et al. Identification of Kaposi's sarcoma-associated herpesvirus (KSHV)-specific cytotoxic T-lymphocyte epitopes and evaluation of reconstitution of KSHV-specific responses in human immunodeficiency virus type 1-Infected patients receiving highly active antiretroviral therapy. J Virol 2002; 76: 2634-2640.
27. Bhaskaran K, Brettle R, Porter K, Walker AS. Systemic non-Hodgkin lymphoma in individuals with known dates of HIV seroconversion: incidence and predictors. AIDS 2004; 18: 673-681.
28. Killebrew D, Shiramizu B. Pathogenesis of HIV-associated non-Hodgkin lymphoma. Curr HIV Res 2004; 2: 215-221.
29. Schwartz RA. Kaposi's sarcoma: An update. J Surg Oncol 2004; 87: 146-151.
30. Chakib A, Hliwa W, Marih L, Himmich H. [Kaposi's sarcoma during HIV infection in Morocco (apropos of 50 cases)] [French]. Bull Soc Pathol Exot 2003; 96: 86-89.
31. Young AC, Mazzullo JM, Simon AR, Skolnik PR. Case report: Kaposi's sarcoma: An unusual presentation. MedGenMed 2001; 3: 8.
32. Barillari G, Sgadari C, Toschi E, Monini P, Ensoli B. HIV protease inhibitors as new treatment options for Kaposi's sarcoma. Drug Resist Update 2003; 6: 173-181.
33. Von Roenn JH. Clinical presentations and standard therapy of AIDS-associated Kaposi's sarcoma. Hematol Oncol Clin North Am 2003; 17: 747-762.
34. Cheung TW. AIDS-related cancer in the era of highly active antiretroviral therapy (HAART): A model of the interplay of the immune system, virus, and cancer. 'On the offensive - the Trojan Horse is being destroyed' - Part B. Malignant lymphoma. Cancer Invest 2004; 22: 787-798.
35. Gallagher B, Wang Z, Schymura MJ, Kahn A, Fordyce EJ. Cancer incidence in New York State acquired immunodeficiency syndrome patients. Am J Epidemiol 2001; 154: 544-556.
36. Skiest DJ, Crosby C. Survival is prolonged by highly active antiretroviral therapy in AIDS patients with primary central nervous system lymphoma. AIDS 2003; 17: 1787-1793.
37. Spina M, Carbone A, Vaccher E et al. Outcome in patients with non-hodgkin lymphoma and with or without human immunodeficiency virus infection. Clin Infect Dis 2004; 38: 142-144.
38. Heselmeyer K, Macville M, Schrock E et al. Advanced-stage cervical carcinomas are defined by a recurrent pattern of chromosomal aberrations revealing high genetic instability and a consistent gain of chromosome arm 3q. Genes Chromosomes Cancer 1997; 19: 233-240.
39. Heselmeyer KMS, Blegen H, Friberg B et al. A recurrent pattern of chromosomal aberrations and immunophenotypic appearance defines anal squamous cell carcinomas. Br J Cancer 1997; 76: 1271-1278.